Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach
Sunil Kumar Tripathi1, Sanjeev Kumar Singh, Poonam Singh
1Computer-Aided Drug Designing and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi-, 630 003 Tamil Nadu, India.
Abstract:
Cyclin-dependent kinases (CDKs) are core components of the cell cycle machinery that govern the transition between phases during cell cycle progression. Abnormalities in CDKs activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs. Their inhibitors have entered in clinical trials to treat cancer. Very recently, Heathcote et al. (J. Med. Chem. 2010, 53:8508-8522) have found a ligand BS194 that has a high affinity with CDK2 (IC(50) = 3 nM) but shows low affinity with CDK1 (IC(50) = 30 nM). To understand the selectivity, we used homology modeling, molecular docking, molecular dynamics, and free-energy calculation to analyze the interactions. A rational three-dimensional model of the CDK1/BS194 complex is built. We found that Leu83 is a key residue that recognizes BS194 more effectively with CDK2 with good binding free energies rather than CDK1. Energetic analysis reveals that van der Waals interaction and non-polar contributions to solvent are favorable in the formation of complexes and amine group of the ligand, which plays a crucial role for binding selectivity between CDK2 and CDK1.
Insights
Researchers investigated why the ligand BS194 binds strongly to cyclin-dependent kinase 2 (CDK2) but weakly to CDK1. Molecular analysis revealed Leu83 and specific interactions are key to this selectivity, aiding anticancer drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Cyclin-dependent kinases (CDKs) regulate cell cycle progression, and their dysregulation is implicated in cancer.
- CDK inhibitors are a promising avenue for anticancer drug development.
- Understanding kinase selectivity is crucial for designing effective targeted therapies.
Purpose of the Study:
- To elucidate the molecular basis for the differential binding affinity of ligand BS194 to CDK2 versus CDK1.
- To identify key residues and interactions responsible for the observed selectivity.
Main Methods:
- Homology modeling to construct a three-dimensional model of the CDK1/BS194 complex.
- Molecular docking and molecular dynamics simulations to analyze binding interactions.
- Free-energy calculations to quantify binding affinities.
Main Results:
- Identified Leucine 83 (Leu83) as a critical residue for BS194 recognition, favoring CDK2 binding.
- Energetic analysis highlighted favorable van der Waals interactions and non-polar solvent contributions.
- The amine group of BS194 was found to be crucial for selective binding between CDK2 and CDK1.
Conclusions:
- The study provides a rational explanation for the selectivity of BS194 towards CDK2 over CDK1.
- Molecular insights gained can guide the design of more potent and selective CDK inhibitors for cancer therapy.
Related Concept Videos
Positive Regulator Molecules
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The Equilibrium Binding Constant and Binding Strength
Inhibition of Cdk Activity
Ligand Binding and Linkage

